Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NOR-SWITCH

Infographic: North Asia

An overview of the five most-commonly researched, largest pharma markets in North Asia.

Research Partnership

- PMLiVE

NICE recommends infliximab biosimilars ahead of Remicade

Newly-acquired Hospira and Napp see their infliximab products backed by the HTA body

- PMLiVE

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

Sanofi reception

Poor Lantus sales sees Sanofi’s diabetes unit fall

French firm hit by insulin pricing pressures and soon faces biosimilar threat

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

- PMLiVE

Remicade biosimilars hit European market

Hospira and Mundipharma begin marketing their version of the blockbuster drug

- PMLiVE

Early win for Pfizer as Remicade biosimilar launches in West Europe

Hospira launchescopycat version of Janssen/MSD’s drug in major European markets

How the focus on patient outcomes has allowed FMCG to enter into healthcare market

Associate Consultant Mette Drabæk talks about how the increase in ability to measure real-world patient outcomes has strengthened the position of the payer when negotiating reimbursement contracts with pharma companies.

Blue Latitude Health

Novartis day

FDA close to first biosimilar approval

US regulator’s advisory board recommends Novartis’ version of Amgen’s Neupogen

- PMLiVE

Biosimilar Remicade reaches market in Japan and India

Nippon Kayaku’s version of arthritis drug was approved in July

- PMLiVE

Online life sciences mapping tool launched

UK opens up database of 5,000 life science companies and sites

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links